Be a Smart Investor
Monday, March 6, 2017
Gainers & Losers Of Mar.6: TGTX, CNCE, DXTR, KURA, ARGS...
TG Therapeutics' phase III trial of TG-1101 in patients with high risk Chronic Lymphocytic Leukemia has met its primary endpoint.
from RTT - Biotech http://ift.tt/2n8dgCN
via
IFTTT
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment